Technical analysis indicates that selling in Oncosil (ASX: OSL) is overdone, likely driven in the past by the broader performance of the ASX and more recently by higher interest rates and inflation. However, the sell-off will taper soon as the chart suggests that selling could likely be overdone. This represents a very good buy opportunity for investors and with expansion and commercialization tend to continue in 2024, the stock could be gearing for a reversal.
Oncosil Nearing Inflection Point - Buy Signal
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.001(10.0%) |
Mkt cap ! $16.66M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.5¢ | $40.14K | 8.018M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 8815555 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 23460600 | 19 |
View Market Depth
| Last trade - 11.41am 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 207149 | ||
| Last updated 10.15am 27/05/2024 ? | |||||
| OSL (ASX) Chart |